Emerging at the UK, retatrutide, a new molecule, is creating considerable interest within the medical community regarding its ability for body management . This dual GIP and GLP-1 receptor agonist appears to deliver a considerable advantage over existing therapies, showing promising results in preliminary clinical trials . Researchers suggest its d